Multiple myeloma

DOI DOI Web Site Web Site PubMed View 1 Remaining Hide
  • ABE Masahiro
    Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School
  • MIKI Hirokazu
    Division of Transfusion Medicine and Cell Therapy, Tokushima University Hospital
  • NAKAMURA Shingen
    Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School

Bibliographic Information

Other Title
  • 多発性骨髄腫
  • タハツセイ コツズイシュ
  • 多発性骨髄腫 : QoLの改善に向けた治療の進歩
  • タハツセイ コツズイシュ : QoL ノ カイゼン ニ ムケタ チリョウ ノ シンポ

Search this article

Abstract

Owing to the positive clinical benefits obtained with new agents, complete remission (CR) can be used as a surrogate for overall survival, and should be achieved. Although multiple myeloma is a heterogeneous disease in terms of myeloma cell- and patient-related risk factors, patients should receive the most effective combination therapy based on proteasome inhibitors and/or immunomodulatory drugs (IMiDs) as backbone medication irrespective of the risks encountered in the setting of induction therapy (“one-size-fits-all” therapy), followed by consolidation/maintenance therapy to achieve CR with the ultimate goal of extended survival. Myeloma-defining biomarkers have been established to identify high-risk smoldering myeloma requiring treatment. The development of salvage treatments yielding better outcomes for relapsed/refractory myeloma is urgently needed. Upcoming novel molecular targeting agents with different modes of action and immunotherapeutic agents will be integrated into myeloma treatment regimens with a great therapeutic impact, and further evolution of the treatment paradigm for multiple myeloma is eagerly anticipated.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 57 (3), 260-269, 2016

    The Japanese Society of Hematology

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top